BACKGROUND & AIMS:Polycystic liver disease (PLD), the most common extrarenal manifestation of autosomal-dominant polycystic kidney disease (ADPKD), has become more prevalent as a result of increased life expectancy, improved renal survival, reduced cardiovascular mortality, and renal replacement therapy. No studies have fully characterized PLD in large cohorts. We investigated whether liver and cyst volumes are associated with volume of the hepatic parenchyma, results from liver laboratory tests, and patient-reported outcomes. METHODS: We performed a cross-sectional analysis of baseline liver volumes, measured by magnetic resonance imaging, and their association with demographics, results from liver laboratory and other tests, and quality of life. The data were collected from a randomized, placebo-controlled trial underway at 7 tertiary-care medical centers to determine whether the combination of an angiotensin I-converting enzyme inhibitor and angiotensin II-receptor blocker was superior to the inhibitor alone, and whether low blood pressure (<110/75 mm Hg) was superior to standard blood pressure (120-130/70-80 mm Hg), in delaying renal cystic progression in 558 patients with ADPKD, stages 1 and 2 chronic kidney disease, and hypertension (age, 15-49 y). RESULTS: We found hepatomegaly to be common among patients with ADPKD. Cysts and parenchyma contributed to hepatomegaly. Cysts were more common and liver and cyst volumes were greater in women, increasing with age. Patients with advanced disease had a relative loss of liver parenchyma. We observed small abnormalities in results from liver laboratory tests, and that splenomegaly and hypersplenism were associated with PLD severity. Higher liver volumes were associated with a lower quality of life. CONCLUSIONS: Hepatomegaly is common even in early stage ADPKD and is not accounted for by cysts alone. Parenchymal volumes were larger, compared with liver volumes of patients without ADPKD or with those predicted by standardized equations, even among patients without cysts. The severity of PLD was associated with altered biochemical and hematologic features, as well as quality of life. ClinicalTrials.gov identifier: NCT00283686.
RCT Entities:
BACKGROUND & AIMS:Polycystic liver disease (PLD), the most common extrarenal manifestation of autosomal-dominant polycystic kidney disease (ADPKD), has become more prevalent as a result of increased life expectancy, improved renal survival, reduced cardiovascular mortality, and renal replacement therapy. No studies have fully characterized PLD in large cohorts. We investigated whether liver and cyst volumes are associated with volume of the hepatic parenchyma, results from liver laboratory tests, and patient-reported outcomes. METHODS: We performed a cross-sectional analysis of baseline liver volumes, measured by magnetic resonance imaging, and their association with demographics, results from liver laboratory and other tests, and quality of life. The data were collected from a randomized, placebo-controlled trial underway at 7 tertiary-care medical centers to determine whether the combination of an angiotensin I-converting enzyme inhibitor and angiotensin II-receptor blocker was superior to the inhibitor alone, and whether low blood pressure (<110/75 mm Hg) was superior to standard blood pressure (120-130/70-80 mm Hg), in delaying renal cystic progression in 558 patients with ADPKD, stages 1 and 2 chronic kidney disease, and hypertension (age, 15-49 y). RESULTS: We found hepatomegaly to be common among patients with ADPKD. Cysts and parenchyma contributed to hepatomegaly. Cysts were more common and liver and cyst volumes were greater in women, increasing with age. Patients with advanced disease had a relative loss of liver parenchyma. We observed small abnormalities in results from liver laboratory tests, and that splenomegaly and hypersplenism were associated with PLD severity. Higher liver volumes were associated with a lower quality of life. CONCLUSIONS:Hepatomegaly is common even in early stage ADPKD and is not accounted for by cysts alone. Parenchymal volumes were larger, compared with liver volumes of patients without ADPKD or with those predicted by standardized equations, even among patients without cysts. The severity of PLD was associated with altered biochemical and hematologic features, as well as quality of life. ClinicalTrials.gov identifier: NCT00283686.
Authors: Thomas Schnelldorfer; Vicente E Torres; Shaheen Zakaria; Charles B Rosen; David M Nagorney Journal: Ann Surg Date: 2009-07 Impact factor: 12.969
Authors: T Ecder; C L Edelstein; A B Chapman; A M Johnson; L Tison; E A Gill; G M Brosnahan; R W Schrier Journal: Nephrol Dial Transplant Date: 1999-05 Impact factor: 5.992
Authors: Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth Journal: Gastroenterology Date: 2009-07-29 Impact factor: 22.682
Authors: Kyongtae T Bae; Fang Zhu; Arlene B Chapman; Vicente E Torres; Jared J Grantham; Lisa M Guay-Woodford; Deborah A Baumgarten; Bernard F King; Louis H Wetzel; Philip J Kenney; Marijn E Brummer; William M Bennett; Saulo Klahr; Catherine M Meyers; Xiaoling Zhang; Paul A Thompson; J Philip Miller Journal: Clin J Am Soc Nephrol Date: 2005-10-26 Impact factor: 8.237
Authors: Lucas H P Bernts; Myrte K Neijenhuis; Marie E Edwards; Jeff A Sloan; Jenna Fischer; Rory L Smoot; David M Nagorney; Joost P H Drenth; Marie C Hogan Journal: Surgery Date: 2020-05-08 Impact factor: 3.982
Authors: Fouad T Chebib; Amber Harmon; Maria V Irazabal Mira; Yeon Soon Jung; Marie E Edwards; Marie C Hogan; Patrick S Kamath; Vicente E Torres; David M Nagorney Journal: J Am Coll Surg Date: 2016-01-14 Impact factor: 6.113
Authors: Jacqueline Bezençon; James J Beaudoin; Katsuaki Ito; Dong Fu; Sharin E Roth; William J Brock; Kim L R Brouwer Journal: Drug Metab Dispos Date: 2019-06-03 Impact factor: 3.922
Authors: Youngwoo Kim; Sonu K Bae; Tianming Cheng; Cheng Tao; Yinghui Ge; Arlene B Chapman; Vincente E Torres; Alan S L Yu; Michal Mrug; William M Bennett; Michael F Flessner; Doug P Landsittel; Kyongtae T Bae Journal: Phys Med Biol Date: 2016-10-25 Impact factor: 3.609
Authors: Carsten Bergmann; Lisa M Guay-Woodford; Peter C Harris; Shigeo Horie; Dorien J M Peters; Vicente E Torres Journal: Nat Rev Dis Primers Date: 2018-12-06 Impact factor: 52.329
Authors: Myrte K Neijenhuis; Tom J G Gevers; Marie C Hogan; Patrick S Kamath; Titus F M Wijnands; Ralf C P M van den Ouweland; Marie E Edwards; Jeff A Sloan; Wietske Kievit; Joost P H Drenth Journal: Hepatology Date: 2016-04-15 Impact factor: 17.425